Research status and progress of the RNA or protein biomarkers for prostate cancer
暂无分享,去创建一个
[1] Chunjiao Song,et al. Predictive significance of TMRPSS2-ERG fusion in prostate cancer: a meta-analysis , 2018, Cancer Cell International.
[2] G. Guelfi,et al. Next Generation Sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research , 2018, Scientific Reports.
[3] Shuanke Wang,et al. Long Noncoding RNA SChLAP1 Accelerates the Proliferation and Metastasis of Prostate Cancer via Targeting miR-198 and Promoting the MAPK1 Pathway , 2018, Oncology research.
[4] S. Hanash,et al. Baseline and longitudinal plasma caveolin‐1 level as a biomarker in active surveillance for early‐stage prostate cancer , 2018, BJU international.
[5] Chunjiao Song,et al. The potential of microRNAs as human prostate cancer biomarkers: A meta‐analysis of related studies , 2017, Journal of cellular biochemistry.
[6] K. D. Sørensen,et al. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis , 2017, International journal of molecular sciences.
[7] Q. Hu,et al. TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer , 2017, Medical Science Monitor.
[8] J. Kench,et al. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Jianmin Wang,et al. Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer. , 2017, Cancer letters.
[10] Mutsushi Yamasaki,et al. Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer. , 2017, Oncology reports.
[11] D. Amadori,et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] M. Boutros,et al. Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker * , 2017, Molecular & Cellular Proteomics.
[13] Wei Wei,et al. MiR‐1, a Potential Predictive Biomarker for Recurrence in Prostate Cancer After Radical Prostatectomy , 2017, The American journal of the medical sciences.
[14] Yan-bo Chen,et al. The function of oxytocin: a potential biomarker for prostate cancer diagnosis and promoter of prostate cancer , 2017, Oncotarget.
[15] Yi-Xiang Liao,et al. Epidermal Growth Factor-Containing Fibulin-Like Extracellular Matrix Protein 1 (EFEMP1) Acts as a Potential Diagnostic Biomarker for Prostate Cancer , 2017, Medical science monitor : international medical journal of experimental and clinical research.
[16] G. Guelfi,et al. Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role , 2016, OncoTargets and therapy.
[17] J. López-Miranda,et al. Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker. , 2016, Cancer letters.
[18] K. Nutahara,et al. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy , 2016, International journal of molecular sciences.
[19] G. Kristiansen,et al. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy , 2016, Oncotarget.
[20] David S. K. Lu,et al. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.
[21] L. Dai,et al. Using Serological Proteome Analysis to Identify Serum Anti‐Nucleophosmin 1 Autoantibody as a Potential Biomarker in European‐American and African‐American Patients With Prostate Cancer , 2016, The Prostate.
[22] R. Skotheim,et al. PBX3 is a putative biomarker of aggressive prostate cancer , 2016, International journal of cancer.
[23] M. Loda,et al. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. , 2016, European urology.
[24] D. Edwards,et al. The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker , 2016, The Prostate.
[25] Johannes Stein,et al. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients , 2016, Epigenetics.
[26] M. Rivera,et al. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer , 2016, Clinical Cancer Research.
[27] M. Liu,et al. Prostate-Specific G-Protein Coupled Receptor, an Emerging Biomarker Regulating Inflammation and Prostate Cancer Invasion. , 2016, Current molecular medicine.
[28] L. Dai,et al. Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer , 2016, Oncotarget.
[29] K. D. Sørensen,et al. Large‐scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels , 2016, Molecular oncology.
[30] L. Bégin,et al. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development. , 2016, Urologic oncology.
[31] Ahmedin Jemal,et al. Annual Report to the Nation on the Status of Cancer, 1975‐2012, featuring the increasing incidence of liver cancer , 2016, Cancer.
[32] M. Brunelli,et al. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review. , 2016, Clinical genitourinary cancer.
[33] G. Kristiansen,et al. TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy , 2016, Virchows Archiv.
[34] P. Leedman,et al. Genetic and cellular studies highlight that A Disintegrin and Metalloproteinase 19 is a protective biomarker in human prostate cancer , 2016, BMC Cancer.
[35] Xin Lu,et al. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer , 2016, Scientific Reports.
[36] J. Osborne,et al. PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer? , 2015, International journal of environmental research and public health.
[37] Chiung-Kuei Huang,et al. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer , 2015, Oncotarget.
[38] H. Klocker,et al. Is Eotaxin‐1 a serum and urinary biomarker for prostate cancer detection and recurrence? , 2015, The Prostate.
[39] Wen Cheng,et al. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer. , 2015 .
[40] L. Manzoli,et al. SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis , 2015, Oncotarget.
[41] Xiao Han,et al. Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer , 2015, Oncotarget.
[42] R. Singal,et al. Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease , 2015, British Journal of Cancer.
[43] G. Guelfi,et al. Stability Assessment of Candidate Reference Genes in Urine Sediment of Prostate Cancer Patients for miRNA Applications , 2015, Disease markers.
[44] R. Shah,et al. Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling. , 2015, Human pathology.
[45] W. Mandecki,et al. Macrophage Inhibitory Cytokine 1 Biomarker Serum Immunoassay in Combination with PSA Is a More Specific Diagnostic Tool for Detection of Prostate Cancer , 2015, PloS one.
[46] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[47] W. Fan,et al. Diagnostic Value of SFRP1 as a Favorable Predictive and Prognostic Biomarker in Patients with Prostate Cancer , 2015, PloS one.
[48] L. Hansson,et al. Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker , 2015, BMC Cancer.
[49] O. Coqueret,et al. Olfactomedin‐4 is a candidate biomarker of solid gastric, colorectal, pancreatic, head and neck, and prostate cancers , 2015, Proteomics. Clinical applications.
[50] C. Stephan,et al. Urinary thiosulfate as failed prostate cancer biomarker – an exemplary multicenter re-evaluation study , 2015, Clinical chemistry and laboratory medicine.
[51] Shun Li,et al. Serum C-reactive protein acted as a prognostic biomarker for overall survival in metastatic prostate cancer patients , 2015, Tumor Biology.
[52] P. Jarzemski,et al. Engrailed-2 protein as a potential urinary prostate cancer biomarker: a comparison study before and after digital rectal examination , 2015, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.
[53] B. Yalcin,et al. Resistance to androgen-pathway drugs in prostate cancer. , 2014, The New England journal of medicine.
[54] K. Kamoi,et al. Evaluation of PSF1 as a prognostic biomarker for prostate cancer , 2014, Prostate Cancer and Prostatic Disease.
[55] J. Hou,et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer , 2014, Oncotarget.
[56] Sweta Rani,et al. miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression , 2014, The Prostate.
[57] E. Ranieri,et al. Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. , 2014, Cancer research.
[58] H. Shahrokh,et al. Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer , 2014, Molecular Biology Reports.
[59] B. Yao,et al. Protein Tyrosine Kinase 7 (PTK7) as a Predictor of Lymph Node Metastases and a Novel Prognostic Biomarker in Patients with Prostate Cancer , 2014, International journal of molecular sciences.
[60] N. Nonomura,et al. Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high‐Gleason prostate cancer , 2014, The Prostate.
[61] T. Ahlering,et al. Urinary nerve growth factor as an oncologic biomarker for prostate cancer aggressiveness. , 2014, Urologic oncology.
[62] Yinghao Sun,et al. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy. , 2014, Anticancer research.
[63] Yuantong Tian,et al. AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression , 2014, Diagnostic Pathology.
[64] Hitendra R. H. Patel,et al. Prostate stem cell antigen – novel biomarker and therapeutic target? , 2014, Expert review of anticancer therapy.
[65] Pasquale Ditonno,et al. Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. , 2013, The Journal of urology.
[66] V. Cheynet,et al. Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer , 2013, Journal of visualized experiments : JoVE.
[67] C. Scholz,et al. MiR-205 Is Progressively Down-Regulated in Lymph Node Metastasis but Fails as a Prognostic Biomarker in High-Risk Prostate Cancer , 2013, International journal of molecular sciences.
[68] L. Mechelli,et al. Circulating microRNAs and Kallikreins before and after Radical Prostatectomy: Are They Really Prostate Cancer Markers? , 2013, BioMed research international.
[69] S. Hilsenbeck,et al. Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer , 2013, Clinical Cancer Research.
[70] M. Rubin,et al. V-ets erythroblastosis virus E26 oncogene homolog (avian)/Trefoil factor 3/high-molecular-weight cytokeratin triple immunostain: a novel tissue-based biomarker in prostate cancer with potential clinical application. , 2013, Human pathology.
[71] Yusuke Nakamura,et al. Plasma low-molecular-weight proteome profiling identified neuropeptide-Y as a prostate cancer biomarker polypeptide. , 2013, Journal of proteome research.
[72] L. Lessard,et al. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. , 2013, European journal of cancer.
[73] R. Kaneva,et al. Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients. , 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[74] S. Bhattacharyya,et al. Arylsulfatase B (N-Acetylgalactosamine-4-Sulfatase): Potential Role as a Biomarker in Prostate Cancer , 2013, Prostate Cancer and Prostatic Diseases.
[75] M. Gleave,et al. Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen , 2013, Cancer medicine.
[76] A. D'Amico,et al. American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010 , 2010, CA: a cancer journal for clinicians.
[77] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[78] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[79] E. Fearon,et al. Cancer progression , 1999, Current Biology.
[80] A. Tewari,et al. The Use of Biomarkers in Prostate Cancer Screening and Treatment. , 2017, Reviews in urology.
[81] J. López-Guerrero,et al. PCA3 as a second-line biomarker in a prospective controlled randomized opportunistic prostate cancer screening programme. , 2017, Actas urologicas espanolas.
[82] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[83] G. Kristiansen,et al. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies. , 2017, The Journal of molecular diagnostics : JMD.
[84] Yuzhuo Wang,et al. Elevated XPO6 expression as a potential prognostic biomarker for prostate cancer recurrence. , 2016, Frontiers in bioscience.
[85] A. Ouhtit,et al. Hoxb13, a potential prognostic biomarker for prostate cancer. , 2016, Frontiers in bioscience.
[86] T. Dellavedova. Prostatic specific antigen. From its early days until becoming a prostate cancer biomarker. , 2016, Archivos espanoles de urologia.
[87] Kai Zhang,et al. MicroRNA-21 in peripheral blood mononuclear cells as a novel biomarker in the diagnosis and prognosis of prostate cancer. , 2016, Cancer biomarkers : section A of Disease markers.
[88] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[89] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.